• Hankook proves its top-tier technological leadership by serving as the official tyre supplier to the ‘Bathurst 6 Hour’ for the second consecutive year
• Ventus TD delivered consistent grip, stability and durability across six hours of racing
• Motorsport-derived R&D reinforces Hankook’s global premium brand positioning

SYDNEY, April 10, 2026 /PRNewswire/ — Global leading tyre company Hankook Tire & Technology (Hankook) announced that Hankook Tyre Australia successfully served as the official tyre supplier to the 2026 Bathurst 6 Hour for the second consecutive year, held from April 3 to 5 at Mount Panorama Circuit. Through this six-hour endurance competition, Hankook reinforced its commitment to high-performance motorsport and advanced tyre technology.

Marking the 10th edition of the Bathurst 6 Hour, the event featured 69 cars competing across multiple classes. Held on the demanding 6.2-kilometre Mount Panorama Circuit, the race stands as Australia’s premier production car endurance event, known for its combination of high-speed straights, technical corners and significant elevation changes.

The 2026 race featured intense competition, with multiple lead changes and strategic battles throughout the six-hour duration. Supercars driver Thomas Randle, alongside Ben and Michael Kavich, secured overall victory in a closely contested finish, highlighting the importance of consistency, strategy and performance in endurance racing at Mount Panorama.

As the official tyre supplier, Hankook Tyre Australia supported the event with its advanced motorsport tyre technology. Since 2025, all competing vehicles have been equipped with the high-performance semi-slick racing tyre ‘Ventus TD’, ensuring stable race performance. Engineered to perform under demanding conditions, Ventus TD delivers high levels of dry grip, consistent handling performance and enhanced durability throughout extended race sessions.

In an endurance racing environment such as Bathurst, sustained tyre performance is critical. Ventus TD demonstrated stable grip and predictable handling across extended stints, enabling teams to optimise race strategy. Its construction and compound are designed to enhance durability, heat resistance and reduced wear under varying track conditions. The tyre’s optimised contact patch and tread design enable balanced load distribution, contributing to consistent performance.

In Australia, Hankook continues to strengthen its sales competitiveness with its flagship tyre brand ‘Ventus’ while actively supporting major local motorsport events, including the First Focus Radical Cup Australia Series, the Precision National Sports Sedans Series and the Hyper Racer Hankook Australian Drivers Championship, thereby expanding its global motorsport footprint.

Hankook Tyre Australia’s participation in the Bathurst 6 Hour reflects its broader commitment to supporting motorsport platforms that demand high levels of performance, safety and technological innovation. Leveraging its global expertise in tyre development, Hankook continues to demonstrate its top-tier technological leadership. Hankook continues to supply racing tyres and sponsor teams across more than 70 major global motorsport competitions, including the ABB FIA Formula E World Championship and the FIA World Rally Championship (WRC), further solidifying the global premium positioning of its brand.

• 38% of finance professionals who personally hold crypto view it as a growth opportunity with strong upside potential
• 96% of professional investors are optimistic about crypto’s future as an asset, vs just 39% of beginner investors
• 25% of finance professionals describe crypto primarily as a high-risk asset — falling to just 1 in 10 among those who personally invest
• 8% of respondents cite payments utility as a reason to hold crypto, yet wider merchant acceptance and regulatory integration are seen as critical drivers of future adoption
• 42% of finance professionals cite regulatory uncertainty as their primary barrier to greater institutional involvement

GENEVA, April 10, 2026 /PRNewswire/ — Sandmark has today published the first edition of its Crypto Intelligence Report, uncovering how credible and reliable intelligence are building real conviction among finance professionals and investors.

Michelle Fotopoulou, Chief Marketing Officer at Sandmark, commenting on the Crypto Intelligence Report

The study captured the attitudes and behaviours of over 5,000 finance professionals and crypto investors across Australia, Brazil, India, Singapore, South Korea, UAE, UK and the US. Conducted in partnership with the global consumer audience insights platform GWI, the report fills a significant gap in existing market research by focusing specifically on the financially literate crypto investors: those working within and alongside the financial industry.

“Most crypto research focuses on retail sentiment. We wanted to understand how finance professionals – people who work with risk and capital every day – actually perceive and engage with crypto. What we found challenges a number of assumptions,” said Michelle Fotopoulou, Chief Marketing Officer at Sandmark.

Experience contextualizes risk

Just one in ten finance professionals who own crypto perceive it as high risk, compared to 25% of the wider professional finance community. Optimism and confidence rise in line with active participation, peaking among institutional investors and long-term holders. Beginners remain the least certain. The data consistently shows that hands-on experience, supported by reliable market intelligence, is what builds genuine conviction.

Regulation is recruitment

Regulatory uncertainty remains the primary barrier to broader institutional participation, alongside volatility and governance concerns. Yet across all respondent groups, crypto is viewed as a long-term strategic asset with strong upside potential, rather than a short-term trade. As regulatory clarity improves, the market’s next growth phase is widely expected to be led by institutions.

Michelle said: “Strong regulation acts as a catalyst for engagement. As jurisdictions put protections in place, activity accelerates, with greater confidence unlocking broader adoption.”

Public figures: formative but divisive

High-profile individuals continue to play an outsized role in shaping sentiment, often in conflicting ways. Among a pre-defined shortlist of public figures, Elon Musk drives the strongest positive sentiment (51%), while Donald Trump generates the most negative (38%), despite also ranking as the second most cited positive influence (17%). Among crypto holders who identify Musk as their strongest positive influence, 77% report high optimism toward crypto’s future as an asset. The study reflects how public figures are capable of simultaneously amplifying enthusiasm and undermining trust.

An evolving but maturing market

Michelle concluded, “It’s fascinating to see the evolution of sentiment in the crypto market, particularly in the case of institutions and finance professionals. While social media drives discovery, real market data is in higher demand. Investors need consistent, actionable market intelligence to understand the evolving crypto ecosystem.”

The Sandmark Crypto Intelligence Report is available here.

About Sandmark

Established in 2025 by a Switzerland-based entrepreneur, Sandmark operates internationally with editorial hubs in Europe, the Middle East, Asia and North America. Sandmark is led worldwide by traditional and new financial media professionals who have decades of experience covering a range of markets from banking to commodities, and FX trading to equities research.

The Sandmark Team is comprised of 20+ global employees – including journalists, researchers and data analysts – that are united in the mission to deliver clear, credible, and context-rich reporting. 

Sandmark Crypto Intelligence Report: first edition of key trends shaping the digital asset landscape

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px^[1], (Pixclara®^[2], Floretyrosine F 18 or ¹⁸F-FET), an investigational PET^[3] agent for the imaging of glioma (brain cancer), and has assigned a PDUFA^[4] goal date of September 11, 2026.

The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients^[5]. Neuroimaging of glioma with ¹⁸F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines®^[6] – and TLX101-Px has been granted Orphan Drug^[7] and Fast Track^[8] designations by the FDA.

“There remains a critical unmet need in improving our ability to image residual glioma after treatment,” said Thomas Hope, MD, Vice Chair, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF). “We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET^[9] available to patients in the United States.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, “Distinguishing tumor progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with ¹⁸F-FET is an important tool in clinical practice worldwide, and the FDA’s acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States.”

Kevin Richardson, CEO, Telix Precision Medicine, added, “The FDA’s acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients.”

Telix’s FY 2026 financial guidance does not include any revenue contribution from TLX101-Px.

About TLX101-Px

TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (iodofalan ¹³¹I), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma^[10]. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

About gliomas

Gliomas are diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) cancer that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors^[11]. In the U.S., there are approximately 24,000 new glioma cases diagnosed annually^[12]. Glioblastoma (GBM) is a high-grade glioma and the most common and aggressive form of primary brain cancer. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[13], with an expected survival duration of 12-15 months from diagnosis^[14]. 

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 
 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and  TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

By Rob Thomas | Senior Vice President, IBM Software and Chief Commercial Officer

ARMONK, N.Y., April 10, 2026 /PRNewswire/ — There is a pattern we keep seeing in technology. When software moves from product to platform and then from platform to infrastructure, the rules change.

IBM Corporation logo.

At the product stage, control can feel like an advantage. Closed systems move fast. They tightly manage the experience. They concentrate value inside a single company. That approach can work at the product stage. But once a technology becomes foundational, once other systems, institutions, and markets begin to rely on it, the bar shifts. At infrastructure scale, openness stops being ideological and starts being practical.

AI is crossing that threshold now.

Anthropic’s limited preview of Claude Mythos brings that reality into sharper focus. The company says the model can discover and exploit software vulnerabilities at a level that few human experts can match, and it has launched a gated initiative, Project Glasswing, to put those capabilities into defenders’ hands first. What matters most is not just the model itself, but what it signals: AI is no longer just a tool people experiment with. It is becoming embedded in how organizations secure systems, write code, make decisions, and create value.

At that point, the core question changes. The issue is no longer only what these models can do. It becomes how they are built, governed, inspected, and improved over time.

History is consistent on this point. As systems grow in importance and complexity, closed development becomes harder to defend. No single company can anticipate every failure mode, every adversarial use, or every operational requirement. Restricting access to powerful systems is an understandable instinct. It can look like caution. But at infrastructure scale, security improves more often through scrutiny than through concealment.

That is the enduring lesson of open source software.

Open source does not eliminate risk. It changes how risk is managed. It allows more researchers, developers, and defenders to examine systems, test assumptions, surface weaknesses, and harden code under real‑world conditions. In security, visibility is not the enemy of resilience. It is often a prerequisite for it.

This matters even more in the age of AI. If frontier models are increasingly capable of finding vulnerabilities, writing exploits, and reshaping the security landscape, we should be cautious about concentrating understanding of those systems inside a small number of companies. Critical technologies tend to be safer when more people can inspect them, challenge them, and improve them.

This is also why open systems do not destroy value. They move it. One of the oldest misconceptions about open source is that it commoditizes innovation. In practice, it usually pushes competition up the stack. As common foundations mature, value shifts toward implementation, reliability, orchestration, trust, and domain expertise. The winners are not the companies that merely own the base layer, but those that know how to apply it best.

We have seen this before with operating systems, cloud infrastructure, and developer tooling. Open foundations expanded participation, accelerated improvement, and created larger markets on top. AI is likely to follow the same path. Even in enterprise technology, leaders increasingly view open source as strategically important, especially for infrastructure modernization and emerging capabilities like AI.

There is another reason openness matters. Who gets to participate shapes what gets built. Narrow access leads to narrow perspectives. Broad access enables more researchers, startups, governments, and institutions to influence how technology evolves and where it is applied. That does not just drive innovation. It builds legitimacy and adaptability.

The Mythos moment should give us pause, but not for the most obvious reason. Yes, the capabilities are striking. Yes, the risks are real. The deeper implication is structural. Once AI becomes critical infrastructure, opacity can no longer be the organizing principle for safety.

For decades, the most reliable model for secure software has been open foundations combined with serious governance, active maintenance, and broad scrutiny. As AI enters its infrastructure phase, that same logic increasingly applies to the models themselves. The more critical the technology, the stronger the case for openness.

If AI is becoming foundational, then openness is no longer a debate. It is a design requirement.

Media contact:
IBM Press Room
ibmpress@us.ibm.com

SINGAPORE, April 10, 2026 /PRNewswire/ — eFuels SEA, Ltd. today announced its launch as a new development platform dedicated to advancing electrofuel, also referred to as eFuel, projects throughout Southeast Asia. The company will utilize Infinium’s ultra-low carbon eFuels technology to develop and deploy commercial-scale production facilities across the region, accelerating the transition to sustainable fuels.

Headquartered in Singapore, eFuels SEA will develop eFuel production facilities that convert captured carbon dioxide and renewable power into drop-in sustainable aviation fuel (eSAF) and other ultra-low carbon products. The platform is supported by an experienced Asia-based management team with expertise in energy markets, project finance, and industrial development, working in collaboration with regional partners.

Infinium, a global leader in ultra-low carbon electrofuels designed to decarbonize transportation and industrial supply chains, will license its proprietary eFuels technology to projects under development by eFuels SEA in Southeast Asia. Infinium’s technology transforms renewable electricity, water, and waste carbon dioxide into high-value liquid fuels that can be used with existing fuel supply infrastructure without modification.

“By leveraging Infinium’s demonstrated technology, we are confident of delivering economic value add, enhancing energy security and achieving climate impact in the region. We plan to work with local partners and community members to accelerate siting of these projects as a complement to local agendas for industrial development, manpower up-skilling and net-zero commitments.” said David Wang, Co-founder & CEO

“Southeast Asia has the industrial capability and policy momentum to implement decarbonization projects to truly become a leader in electrofuels. There is also an urgent need to reduce dependency on fossil fuel with sustainable energy thereby enhancing energy security.” said Tienleong Tan, Strategic Advisor, eFuels SEA. Infinium Energy is a leader in the commercialization of ultra-low carbon eFuels, operating the world’s first commercial-scale eFuels plant in Corpus Christi, Texas since 2023. A second facility based on Infinium technology is currently under construction in Pecos, Texas.

“We are pleased to collaborate with eFuels SEA to expand access to eFuels in Southeast Asia, a region uniquely positioned to scale production of sustainable aviation fuel and other low-carbon fuels” said Robert Schuetzle, CEO and Founder of Infinium.

Reducing the region’s carbon impact and its dependence on fossil fuels

Southeast Asia offers a unique combination of fuel demand fundamentals and sources of renewable energy. Countries including Singapore, Malaysia, Thailand and Indonesia are advancing hydrogen and carbon management strategies that align with large-scale eFuel deployment. These developments create favorable conditions for new projects that can support domestic decarbonization goals while positioning the region as an exporter of sustainable fuels.

Accelerating Asia’s Energy Transition

eFuels SEA plans to target development of 3-5 projects across multiple Southeast Asian countries. By combining regional project development expertise with Infinium’s advanced technology platform, the company aims to scale production to meet both domestic demand and international market opportunities.

About Infinium

Infinium is reimagining how the world powers, moves, and computes. Through Infinium Energy™, the company transforms waste carbon into ultra-low carbon eFuels that decarbonize aviation, industry, and transport. Through Infinium Edge™, Infinium advances next-generation thermal infrastructure for data centers, removing heat as a constraint to enable more efficient, high-performance computing. Grounded in chemistry and energy systems expertise, Infinium’s platforms turn carbon and heat from limits into opportunities. For more information, visit www.infiniumco.com.

About eFuels SEA, Ltd.

Based in Singapore, eFuels SEA, Ltd. is a regional platform focused on developing, financing, producing and supplying electrofuels across Southeast Asia. The company leverages renewable power, carbon capture, and Infinium’s demonstrated technology to produce sustainable fuels for aviation, shipping, and industry. With a new industrial and financial ecosystem and re-skilling of new labor force, eFuels SEA believes it can transform the region’s carbon liabilities into energy assets. For more information, visit www.efuelssea.com

CONTACT: Liz Myers, press@infiniumco.com